Brief: Renovorx Reports First Quarter 2023 Financial Results And Operational Highlights
15/05/2023 13:36
RenovoRx Inc RNXT.O :
* RENOVORX REPORTS FIRST QUARTER 2023 FINANCIAL RESULTS AND
OPERATIONAL HIGHLIGHTS
* RENOVORX INC - CASH AND CASH EQUIVALENTS AS OF MARCH 31,
2023,
WERE $3.7 MILLION
Source text for Eikon: ID:nBw8d7qPja
Further company coverage: RNXT.O
Recent news on RenovoRx
See all newsBrief: RenovoRx Gets FDA Orphan Drug Designation For Oxaliplatin To Treat Pancreatic Cancer
RenovoRx Q1 revenue rises as number of active cancer centers increase
RenovoRx 2025 net loss widens on higher operating expenses
Brief: RenovoRx FY Net Income USD -11.168 Million
U.S. STOCKS ON THE MOVE-Vertex Pharma, U.S. Energy Corp, SoFi Technologies